Cass Review: what the British report on care for transgender youth says

The Cass Review is the independent review report on gender identity services for children and adolescents commissioned by NHS England in 2020 and published in its final version on April 10, 2024. It quickly became one of the most cited — and most misunderstood — documents in the international debate on care for minors with gender dysphoria. It has been used as an argument by opposing political positions, often selectively citing its conclusions. In this article, we examine what the report actually says, how it was conducted, what criticisms it has received from the scientific community, and what has concretely changed as a result of its publication.

Who is Hilary Cass and why the report was commissioned

Hilary Dawn Cass, now Baroness Cass, is a British pediatrician born in 1958. She served as president of the Royal College of Paediatrics and Child Health and is an honorary consultant in pediatric disability at the Evelina Hospital in London. Her background is in general pediatrics and developmental neurology: she had no prior specific experience in gender medicine before the appointment.

NHS England assigned her the review in September 2020 within a specific context: the Gender Identity Development Service (GIDS) at the Tavistock and Portman NHS Foundation Trust — the only pediatric gender service in the English National Health Service — was facing a rapid increase in referrals, internal criticism from clinicians about the adequacy of assessments, a journalistic investigation, and concerns raised by an internal review. Referrals to GIDS had gone from a few hundred per year in the early 2010s to nearly 5,000 per year, with a significant demographic shift: the majority of new referrals were adolescents assigned female at birth, rather than the male-assigned children who had historically constituted most patients.

The mandate of the review was to examine the entire service structure — not just medications — and to make recommendations for improving its quality and safety.

What it examined: mandate and methodology

The Cass Review was not a systematic literature review in the technical sense. It was an independent service review, which included:

• Hearings with hundreds of clinicians, patients, families, and researchers
• A series of systematic reviews of the literature commissioned to the University of York, on: international guidelines, social transition, puberty blockers, hormone therapy, psychosocial treatments
• An analysis of the GIDS clinical dataset
• A mapping of services in other countries

The final report is over 400 pages long and is accompanied by the York systematic review reports. It makes 32 recommendations on: referral pathways, clinical assessment, treatments, service organization, staff training, data collection, research, and governance.

It is important to understand this distinction: the Cass Review is not itself a clinical study. It did not produce new patient data. It evaluated the quality and consistency of existing data and the adequacy of the care system.

Key conclusions

The report begins from a fundamental observation: the evidence base available for medical treatments for minors with gender dysphoria is of insufficient quality to support robust clinical recommendations. According to Cass, this does not imply that treatments are ineffective, but that the studies conducted up to that point had important methodological limitations — small samples, absence of control groups, short follow-up, selection bias — that made it impossible to draw definitive conclusions.

The main recommendations include:

• Creating a regional network of specialized services, replacing the centralized GIDS model
• Ensuring holistic assessments that take into account all dimensions of well-being (mental health, neurodevelopment, family history, etc.) and not just gender dysphoria in a narrow sense
• Considering social transition — the change of name, pronouns, and gender expression — as an active intervention that can have significant effects on development, rather than as a simple preference with no clinical consequences
• Making puberty blockers available only within clinical trials, since the existing evidence was not sufficient to qualify them as routine clinical practice
• Prescribing hormone therapy for 16-17 year olds only with extreme caution, through a national multidisciplinary team
• Investing in quality longitudinal research to fill the identified gaps

The report does not recommend denying care to young transgender people. It recommends that care be delivered within structures that ensure thorough assessments, monitoring, and production of quality data.

What it says about puberty blockers

This is the part of the report that received the most media attention, often with excessive simplification.

The Cass Review, through the York systematic reviews, analyzed the available studies on puberty blockers (GnRH agonists, such as triptorelin) for gender dysphoria. The York team applied study quality assessment criteria and concluded that the majority of available studies had methodological limitations too significant to allow reliable conclusions about:

• The effect on gender dysphoria symptoms
• Psychological and psychosocial well-being
• Cognitive development
• Cardiometabolic risk
• Long-term fertility

The report notes that studies conducted within the GIDS itself had not replicated the positive results of the original Dutch studies: the London clinic had documented that “our results were different from the Dutch ones.”

Regarding bone density, the report notes that blockers reduce bone mass accumulation during the treatment period. Some studies suggest partial recovery after discontinuation or initiation of hormone therapy, but long-term evidence remains limited.

The most discussed point concerns the “time to reflect” hypothesis: the premise that blockers offer a pause to allow young people to explore their identity without the irreversible changes of puberty. The report observes that 98% of adolescents who started blockers in the GIDS context subsequently proceeded to cross-sex hormone therapy, casting doubt on whether the intervention functioned as a neutral pause. The report does not claim that blockers are harmful; it states that the evidence for their effectiveness for this specific indication does not reach the standard necessary to justify their routine use outside of clinical trials.

What it says about hormone therapy for adolescents

The report also addresses hormone therapy (testosterone for trans boys, estrogen for trans girls) for 16-17 year olds — the age at which GIDS normally prescribed it.

The Cass Review concludes that, while the evidence on hormone therapy in adolescents is slightly more robust than that on blockers, it remains insufficient to justify routine prescribing without additional structural safeguards. It recommends that it be prescribed only by a national multidisciplinary team and with “extreme caution,” taking into account the overall clinical picture of each individual.

The report does not recommend an absolute minimum age of 18 for hormone therapy as a general principle, but signals that access for 16-17 year olds should be managed with a higher level of supervision than what GIDS provided.

Critiques of the Cass Review

The report generated diverse reactions within the scientific community. The most articulate methodological critiques come from multiple fronts.

WPATH and USPATH critiques (May 2024) contest that the report deliberately excluded patients, families, and experts in trans care from the review process, that it applies evidence quality criteria selectively, and that the recommendations often do not derive directly from the data presented in the systematic reviews. WPATH also notes that Hilary Cass had no specific clinical experience in gender medicine before the appointment.

The Yale Integrity Project (a group of researchers and academics) published a detailed critique, observing that the report introduces GRADE system terminology for evidence assessment without rigorously applying its methodology, and effectively adopts higher evidence standards for gender-affirming interventions than those applied in other areas of pediatrics.

The most specific methodological critiques concern the York systematic reviews: the study pre-registrations indicated that the MMAT (Mixed Methods Appraisal Tool) would be used to assess the quality of included studies, but the published reviews used a modified version of the Newcastle-Ottawa Scale instead. This undisclosed and unjustified change of tool led to the exclusion of approximately 48% of potentially relevant studies on blockers and 36% of those on hormone therapy. Critics have argued that this methodological change produced a systematically smaller and less representative corpus of included studies.

Another recurring critique concerns study language: the York team excluded literature not published in English, eliminating a significant volume of research conducted in countries such as the Netherlands, Sweden, Germany, and others.

The Endocrine Society stated that it maintains its position in favor of gender-affirming care for adolescents, observing that the Cass Review does not contain new research contradicting its own guidelines.

It should be noted that there are also defenders of the report within the scientific community, who value its transparency about the limitations of available evidence and its push toward producing higher-quality data.

What changed in the United Kingdom after the report

The institutional consequences of the Cass Review in the United Kingdom were immediate and significant.

GIDS closed in March 2024, even before the publication of the final report. In its place, NHS England opened two new regional services: one in the northwest (with locations at the Alder Hey Children’s NHS Foundation Trust in Liverpool and the Royal Manchester Children’s Hospital) and one in the south (with locations at Great Ormond Street Hospital, Evelina London Children’s Hospital, and the South London and Maudsley NHS Foundation Trust). The goal is to expand the network to eight regional services.

NHS England suspended routine prescribing of blockers for minors as early as March 2024, anticipating the report’s publication. In May 2024, following the Cass Review recommendations, this suspension was formalized with a temporary measure. In December 2024, the British government made the ban indefinite, to be reviewed in 2027, extending the ban to the private sector through a ministerial order that provides criminal penalties of up to two years of imprisonment for unauthorized prescribing. A controlled clinical trial — the “Pathways trial” — was announced in November 2025 and is expected to begin initial enrollment in 2026.

For hormone therapy, NHS England updated its guidelines requiring more thorough assessments and supervision by a national multidisciplinary team, but did not introduce a ban equivalent to that on blockers.

The new services adopt a care model more explicitly oriented toward mental health and neurodevelopment, with systematic assessment of comorbidities before any medical intervention.

The Nordic countries: what actually changed

In public debate, Sweden and Finland are often cited as countries that have “banned” care for trans youth, anticipating the conclusions of the Cass Review. This characterization is inaccurate.

Finland updated its clinical guidelines in June 2020, before the conclusion of the Cass Review. The National Council for Health and Welfare (THL) established that hormonal interventions for minors must be considered with “great caution” and that irreversible treatments should not be initiated. The guidelines set more restrictive criteria: gender dysphoria with early childhood onset, long duration, absence of significant psychiatric comorbidities, and documented ineffectiveness of psychotherapeutic pathways. Treatments were not banned by law: they remain possible, but with much more selective access criteria.

Sweden in February 2022 issued new guidelines through its National Board of Health and Welfare (Socialstyrelsen): hormonal treatments for minors with gender dysphoria were limited to “exceptional cases,” with thorough individual assessment. The official rationale was that the risks of hormonal treatments in this age group “most likely outweigh the potential benefits” for the majority of patients. The Karolinska clinic in Stockholm stopped prescribing blockers and hormones to minors outside of clinical trials, but other centers continued under the new criteria. Here too: significant clinical restriction, not an absolute legislative ban.

Both countries modified their approach in response to concerns about the quality of available evidence, concerns similar to those of the Cass Review, although with differences in clinical and demographic context.

An analysis published in 2025 in a Nordic academic journal documents that gender care services in Nordic countries continue to operate, with more limited access and more selective criteria than a decade ago, but not with closed doors.

What remains open

The Cass Review highlighted a real problem: the evidence base for pediatric gender care is less solid than it was often represented, and requires investment in quality longitudinal research. On this point, there is broad agreement even among those who criticize the report.

The disagreement mainly concerns three issues:

Evidence criteria: critics argue that the report applies higher standards to gender-affirming care than those typically required for other pediatric interventions in contexts of clinical urgency, creating an asymmetry that is not justified by scientific logic alone.

Risk interpretation: the report focuses on the insufficiency of evidence of benefit, but critics note that the risks of not providing care — prolonged psychological distress, development of unwanted irreversible sex characteristics — do not receive the same analytical treatment.

Transferability of conclusions: the report concerns GIDS and NHS England. Whether and to what extent its conclusions apply to other healthcare systems, with different care structures, demographics, and clinical contexts, is a question that remains open.

The scientific debate is active, with new publications examining both the evidence on gender-affirming care for minors and the methodology of the Cass Review itself. Following the primary literature — rather than its second and third-hand interpretations — remains the most reliable way to form an understanding of the actual state of knowledge.